Latest / Practice Point®: Pulmonology
Episode 29 - Module 4: The Promise of Precision ILD Medicine: From Pulmonary Vascular Clues to Emerging Therapies
The treatment landscape for IPF and PPF is evolving rapidly, creating new opportunities for more personalized care. Explore the latest clinical evidence from the FIBRONEER program evaluating nerandomilast and the TETON trials evaluating inhaled treprostinil, alongside emerging therapies such as admilparant and deupirfenidone. Expert faculty examine novel mechanisms of action, treatment tolerability, combination therapy, and the potential to target multiple pathways involved in fibrotic lung disease. Consider how these developments may reshape treatment selection, longitudinal monitoring, and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.